Aumolertinib Combined with Carbamazepine and Intrathecal Pemetrexed for EGFR-mutated LM NSCLC with Symptomatic Epilepsy

被引：0
|
作者：
Li, L. [1 ]
Yang, M. [2 ]
Huang, D. Y. [1 ]
Liu, F. [2 ]
Zhang, L. [3 ]
Song, X. W. [1 ]
Lv, Y. J. [1 ]
Teng, C. [1 ]
Fan, C. J. [1 ]
Tian, D. [1 ]
Shen, W. X. [1 ]
Jiang, Q. Y. [1 ]
Lu, D. [1 ]
Xin, T. [1 ]
机构：
[1] Harbin Med Univ, Affiliated Hosp 2, Harbin, Peoples R China
[2] China Japan Friendship Hosp, Beijing, Peoples R China
[3] Daqing Oilfield Gen Hosp, Daqing, Heilongjiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Aumolertinib; Intrathecal; injection; Symptomatic epilepsy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-42
引用
收藏
页码：S351 / S351
页数：1
相关论文
共 50 条
  • [21] The Optimal Intervention Timing of Aumolertinib Combined with HFSRT for EGFR Mutated NSCLC Patients with Multiple Brain Metastasess
    Shao, Q.
    Li, J.
    Wang, J.
    Wang, W.
    Li, F.
    Li, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S656 - S656
  • [22] Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor
    Zhang, Yaoshuai
    Li, Yongping
    Han, Yuehua
    Li, Min
    Li, Xian
    Fan, Fangtian
    Liu, Hao
    Li, Shanshan
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 945
  • [23] Liquid and Solid Rebiopsies in EGFR-Mutated NSCLC Patients
    Nunes, D.
    Dansin, E.
    Lamblin, C.
    Wasielewski, E.
    Descarpentries, C.
    Gregoire, V.
    Copin, M. C.
    Escande, F.
    Cortot, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2237 - S2238
  • [24] CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (10): : E516 - E516
  • [25] Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    John, Thomas
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu Thi
    Dechaphunkul, Arunee
    Kowalski, Dariusz
    Poole, Lynne
    Bolanos, Ana
    Rukazenkov, Yuri
    Wu, Yi-Long
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (02): : 137 - 147
  • [26] Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
    Planchard, D.
    Janne, P. A.
    Cheng, Y.
    Yang, J. C. -H.
    Yanagitani, N.
    Kim, S-W
    Sugawara, S.
    Yu, Y.
    Fan, Y.
    Geater, S. L.
    Laktionov, K.
    Lee, C. K.
    Valdiviezo, N.
    Ahmed, S.
    Maurel, J-M
    Andrasina, I
    Goldman, J.
    Ghiorghiu, D.
    Rukazenkov, Y.
    Todd, A.
    Kobayashi, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (21): : 1935 - 1948
  • [27] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
    da Silva, L. L.
    Matsas, S.
    Aguiar, P., Jr.
    Taveira, G. M. T.
    Barcelos, I. F.
    Lopes, G. L., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
  • [28] FDA approval of Amivantamab-Vmjw in combination with carboplatin and pemetrexed for EGFR-mutated NSCLC: a new therapeutic milestone
    Hassan, Ibrahim Nagmeldin
    Ibrahim, Muhsin Nagmeldin Hassan
    ANNALS OF MEDICINE AND SURGERY, 2025, 87 (03): : 1111 - 1113
  • [29] EGFR-Mutated Pulmonary Choriocarcinoma Combined With Adenocarcinoma
    Shigematsu, Yasuyuki
    Nakano, Kaoru
    Uchibori, Ken
    Inamura, Kentaro
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (11) : 1318 - 1322
  • [30] Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).
    Lu, Shun
    Dong, Xiaorong
    Jian, Hong
    Chen, Jianhua
    Chen, Gongyan
    Sun, Yuping
    Ji, Yinghua
    Wang, Ziping
    Shi, Jianhua
    Lu, JunGuo
    Chen, Shaoshui
    Lv, Dongqing
    Zhang, Guojun
    Liu, Chunling
    Li, Juan
    Yu, Xinmin
    Lin, Zhong
    Yu, Zhuang
    Wang, Zhehai
    Cui, Jiuwei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345